Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 1423 results for primary care

  1. GPs located in or near emergency departments:- What is the clinical and cost effectiveness of having GPs within or adjoining emergency departments?

    College of Surgeons, is that every emergency department should include a primary care out-of-hours facility. This approach deserves...

  2. Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA1064)

    Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.

  3. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

  4. Relaxation and biofeedback:- What is the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related outcomes?

    therapy, computer-aided biofeedback therapy and attention control in primary care. Participants should be adults with a positive...

  5. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

  6. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

  7. BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)

    NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .

  8. Cochlear implants for children and adults with severe to profound deafness (TA566)

    Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.

  9. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

  10. Icare rebound tonometer to measure intraocular pressure (MIB57)

    NICE has developed a medtech innovation briefing (MIB) on the Icare rebound tonometer to measure intraocular pressure

  11. Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

    Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.

  12. TopClosure Tension Relief System for wound closure (MIB97)

    NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .

  13. Good practice guidance – Integrated process statement (PMG12)

    This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

  14. Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for marginal zone lymphoma after anti-CD20-based treatment in adults.

  15. Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

    Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.